← All compounds
Well Researched

Melanotan II

Synthetic Melanocortin Peptide | Tanning & Sexual Function

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production for skin tanning and has additional effects on sexual arousal and appetite suppression. Originally developed at the University of Arizona as a sunless tanning agent, it has gained attention for its dual effects on pigmentation and sexual function through melanocortin receptor activation.

Daily dose

0.25-1mg

Frequency

1-2x daily

Cycle length

4-8 weeks

Storage

2-8°C

Key benefits

Rapid tanning without UV exposure, enhanced libido and sexual function, appetite suppression, and improved mood through melanocortin activation.

How it works

Binds to melanocortin receptors (MC1R, MC3R, MC4R, MC5R) throughout the body. MC1R activation stimulates melanocytes to produce eumelanin, while MC4R affects sexual arousal and appetite regulation.

Dosage protocols

Goal

Initial Loading

Dose

0.25mg · Daily

Route

Subcutaneous

Goal

Tanning Maintenance

Dose

0.5-1mg · 2-3x weekly

Route

Subcutaneous

Goal

Sexual Enhancement

Dose

0.5-1mg · As needed

Route

Subcutaneous

Goal

Minimal Side Effects

Dose

0.1-0.25mg · Every other day

Route

Subcutaneous

Goal

Photoprotection

Dose

0.5mg · 2x weekly

Route

Subcutaneous

Research indications

skin Health

UV-Free TanningStimulates natural melanin production for darker skin tone without sun damage
PhotoprotectionIncreased melanin provides natural SPF and reduces sunburn risk
Even PigmentationPromotes uniform tanning and may help with certain pigmentation disorders

hormonal

Enhanced LibidoIncreases sexual desire in both men and women through central effects
Erectile FunctionImproves erectile quality and spontaneous erections in men
Female ArousalEnhances genital arousal and sexual satisfaction in women

metabolic

Appetite SuppressionReduces food intake through MC4R activation in hypothalamus
Fat Loss SupportMay enhance fat oxidation and metabolic rate
Glucose MetabolismEmerging evidence for improved insulin sensitivity

Administration

injectable
topical
nasal

Interactions

Use Caution
PT-141 (Bremelanotide)Both act on melanocortin receptors - combining may cause excessive side effects including nausea and blood pressure changes
Avoid Combination
Alpha-MSHRedundant mechanism - both stimulate same melanocortin receptors, increasing risk of side effects without additional benefit
Monitor Combination
Cialis/ViagraMay enhance sexual effects - monitor for prolonged erections and cardiovascular effects, especially blood pressure
Monitor Combination
Blood Pressure MedicationsMT-II can affect blood pressure - monitor closely if combining with antihypertensives
Compatible
BPC-157No known interactions - different mechanisms of action and receptor targets
Compatible
Growth Hormone PeptidesNo documented interactions - work through different pathways (GHRH/ghrelin vs melanocortin)
Monitor Combination
Appetite SuppressantsMT-II has appetite suppressing effects - monitor for excessive appetite reduction when combining
Unknown
Thyroid MedicationsNo specific studies on interaction - consult healthcare provider as both can affect metabolism

Safety notes

Start with very low dose (0.1-0.25mg) to assess tolerance

Nausea is common - can pre-treat with antiemetic if needed

Monitor moles and freckles for changes in size or color

Stay hydrated to minimize headaches and flushing

Avoid if history of melanoma or dysplastic nevi

Blood pressure may increase temporarily after injection

Research studies

Cardiovascular Effects Assessment (2018)

Human | Various doses | Acute monitoring | Mild BP elevation

Comprehensive cardiovascular monitoring revealed transient increases in blood pressure and heart rate, typically mild and self-limiting but requiring consideration in at-risk populations.

Photoprotection in Fair-Skinned Individuals (2015)

Human (Fitzpatrick Type I-II) | 0.1mg/kg | 3 months | Reduced sunburn incidence

Long-term study showed sustained increase in melanin production and significant reduction in UV-induced erythema in individuals with high sunburn susceptibility.

Female Sexual Arousal Disorder Trial (2004)

Human (Female) | 0.025mg/kg | Single dose | 73% reported arousal

Crossover study in premenopausal women with sexual arousal disorder showed significant increases in genital arousal and sexual desire within 24 hours of administration.

Appetite and Food Intake Study (2001)

Human | 1mg daily | 6 weeks | 15% reduction in caloric intake

Demonstrated significant reduction in food intake and modest weight loss through central melanocortin receptor activation, particularly MC4R in hypothalamus.

Phase II Trial of Melanotan II in Erectile Dysfunction (2000)

Human | 0.025mg/kg | 3 months | 80% response rate

Double-blind placebo-controlled study showed significant improvement in erectile function in men with psychogenic ED, with effects beginning within 1-2 hours of subcutaneous injection.

Melanogenesis and UV Protection Study (1999)

Human | 0.16mg/kg daily | 10 days | Increased melanin density

Demonstrated significant increase in eumelanin content and skin pigmentation with corresponding increase in UV protection factor, achieving natural tan without UV exposure.